News|Articles|November 19, 2026

Neflamapimod Phase 2a Data in Primary Progressive Aphasia Show Exposure-Linked NfL Decline

Listen
0:00 / 0:00

Key Takeaways

  • The 36-week design includes 24-week open-label dosing followed by 12-week randomized withdrawal (continue vs placebo), enrolling 25 patients across US (40 mg TID) and UK (80 mg BID) sites.
  • Baseline biomarker profiling showed elevated NfL in most participants (72% >1 SD above controls), whereas GFAP elevation was uncommon (16%), suggesting prominent axonal injury relative to astroglial signal.
SHOW MORE

In a phase 2a trial presented at CTAD 2026, neflamapimod kept plasma NfL stable in nonfluent variant primary progressive aphasia over 24 weeks.

Interim 24-week data from an ongoing phase 2a trial (NCT07033481) showed that plasma neurofilament light chain (NfL) levels remained stable in patients with nonfluent variant primary progressive aphasia (nfvPPA) treated with neflamapimod (CervoMed), an investigational oral p38α inhibitor. Presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, held November 16 to 19, 2026, in Boston, Massachusett, participants with the highest drug exposure had a median NfL decrease.1,2

“One of the most devastating aspects of nonfluent variant PPA is that patients progressively lose their ability to speak and communicate,” phase 2a trial investigator Ian M. Grant, MD, told NeurologyLive®. “Unlike other forms of dementia, including Alzheimer’s disease, where patients are often unaware and personally unbothered by their symptoms, patients with nonfluent variant PPA are very much aware of their symptoms, adding to the frustration and impact on their quality of life. They know what they want to say, but increasingly cannot express it, profoundly affecting their independence and relationships.”

“At this point we have no disease modifying therapies for them, and it’s encouraging to see the continued stability of neurofilament light chain levels over the first 24 weeks of this study, and especially notable to see the reduction among those with higher exposure to neflamapimod,” Grant, assistant professor of neurology at Northwestern University Feinberg School of Medicine, added. “These early findings are intriguing and suggest that neflamapimod may be affecting the underlying neurodegenerative process, supporting further study in nonfluent variant PPA and suggesting potential utility in a variety of other progressive neurodegenerative conditions.”

Study Design

The 36-week trial enrolled 25 participants aged 40 to 85 years with nfvPPA at 7 sites in the US and UK. Participants receive 24 weeks of open-label neflamapimod, followed by a 12-week double-blind, randomized withdrawal in which they are assigned 1:1 to continue treatment or switch to placebo. The US cohort (n = 19) received 40 mg 3 times daily (TID), and the UK cohort (n = 6) received 80 mg twice daily (BID).1,2

At baseline, mean age was 69.5 years, and mean plasma NfL was 45.7 pg/mL, with 72% of participants more than 1 SD above the healthy control mean. Plasma glial fibrillary acidic protein (GFAP) was elevated in only 16%.2

NfL Findings by Drug Exposure

Biomarker data through week 24 were available for the US cohort. In a pharmacokinetic-pharmacodynamic analysis of 18 participants, those in the upper tertile of trough plasma drug concentration (Ctrough; n = 6) had a median NfL change of −4.5 pg/mL from baseline, whereas those in the lower 2 tertiles (n = 12) had a median increase of 4.35 pg/mL. The lowest Ctrough in the upper tertile was 4.3 ng/mL, and the highest in the lower tertiles was 3.5 ng/mL.2

READ MORE: Mevidalen Misses Primary End Point in Phase 2 Alzheimer Trial

Investigators noted that trough levels achieved with 40 mg TID were at the low end of those seen in prior studies, and that the upper-tertile result was consistent with an approximately 4-ng/mL threshold for pharmacologic activity identified in earlier dementia with Lewy bodies (DLB) and Alzheimer disease studies. For context, plasma NfL in untreated nfvPPA rises by a median of approximately 9 pg/mL per year, according to natural history data cited by the investigators.2,3 No P values or statistical comparisons were reported.

Safety

Neflamapimod was generally well tolerated, with no serious adverse events. The most common treatment-emergent adverse events were falls and diarrhea, each reported in 4 of 25 participants (16%), all mild. One participant discontinued treatment after meeting protocol-defined criteria for alanine and aspartate aminotransferase elevations; the participant was asymptomatic, with no bilirubin elevation, and the elevations resolved after discontinuation.2

Background

A subtype of frontotemporal dementia, nfvPPA progressively impairs speech production while largely sparing word comprehension; CervoMed estimates it affects 10,000 to 15,000 people in the US. Neflamapimod, which crosses the blood-brain barrier, selectively inhibits the α isoform of p38 MAP kinase, which is implicated in neuroinflammation and synaptic dysfunction. It holds FDA Orphan Drug designation for frontotemporal dementia, including nfvPPA.1

Exposure has been a recurring theme for the drug. In the phase 2b RewinD-LB trial (NCT05869669) in DLB (n = 159), neflamapimod did not separate from placebo on the Clinical Dementia Rating–Sum of Boxes, but trough concentrations were lower than expected, and exploratory analyses favored the drug among participants with above-median exposure.4

Limitations and Next Steps

The interim data come from a small, open-label cohort without a concurrent control, and the exposure-based subgroups included as few as 6 participants. Week-24 biomarker data from the UK 80-mg BID cohort are expected in the first quarter of 2027, with clinical results planned for the AD/PD conference in March 2027. CervoMed also plans to use a new 50-mg tablet, allowing 100-mg BID dosing, in future studies.1

“Rapid increases plasma neurofilament light chain levels are a hallmark of the neurodegeneration in nonfluent variant PPA, and we’re highly encouraged to see the stability of these levels across patients in our Phase 2a study, and the decline in those with the highest neflamapimod exposure,” John Alam, MD, chief executive officer at CervoMed, told NeurologyLive. “These results provide an efficacy signal that neflamapimod may be slowing the progression of neuronal damage in nonfluent variant PPA and is consistent with what we’ve seen with neflamapimod in patients with dementia with Lewy bodies. We’re looking forward to sharing the clinical and higher-dose biomarker data from this study next year at the AD/PD conference in March 2027 and better understanding whether these effects may translate into meaningful clinical benefits.”

Click here to view more coverage of CTAD 2026.

REFERENCES
1. CervoMed presents interim data at CTAD 2026 showing neflamapimod reduces neurodegeneration biomarker in nonfluent variant primary progressive aphasia. News release. CervoMed. November 16, 2026. Accessed November 18, 2026. https://ir.cervomed.com/news-releases/news-release-details/cervomed-presents-interim-data-ctad-2026-showing-neflamapimod
2. Grant IM, Botha H, Honig LS, et al. Initial neurodegeneration biomarker results from a phase 2a clinical trial of neflamapimod in patients with nonfluent variant primary progressive aphasia. Presented at: 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference; November 16-19, 2026; Boston, MA. Poster P045.
3. Sheth U, Öijerstedt L, Heckman MG, et al. Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders. Mol Neurodegener. 2025;20(1):30. Published 2025 Mar 12. doi:10.1186/s13024-025-00821-4
4. Taylor JP, Alam JJ, Gomperts SN, et al. A Phase 2b randomized clinical trial of the oral p38α inhibitor neflamapimod in dementia with Lewy bodies (DLB). Preprint. Res Sq. 2026;rs.3.rs-10623740. Published 2026 Aug 14. doi:10.21203/rs.3.rs-10623740/v1

Related to this article